AGENDA

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation/Presenter</th>
</tr>
</thead>
</table>
| 8:30 A.M. | Call to Order and Opening Remarks  
Introduction of Committee  
Ruth Lynfield, M.D.  
Acting Chair, VRBPAC |
|           | Conflict of Interest Statement  
Sujata Vijh, Ph.D.  
Designated Federal Officer,  
VRBPAC, FDA |
|           | Topic: Strain Selection for the Influenza Virus Vaccines for the 2016-2017 Influenza Season |
| 8:45a.m.  | Introduction  
Anissa Cheung, M.Sc.  
Regulatory Coordinator  
Division of Viral Products  
Office of Vaccines Research and Review  
CBER/FDA |
| 8:55 a.m. | U.S. Surveillance  
Lisa Grohskopf, M. D., M. P.H.  
CAPT. USPHS  
Associate Chief for Policy & Liaison Activities,  
Epidemiology & Prevention Branch, Influenza Division  
Centers for Disease Control and Prevention |
| 9:20 a.m. | World Surveillance/ Virus Characterization  
Jacqueline Katz, Ph.D.  
Deputy Director (Acting),  
Influenza Division Director,  
WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza,  
Center for Immunization & Influenza,  
Center for Immunization & Respiratory Diseases  
Centers for Disease Control and Prevention |
<p>| 10:20 a.m.| BREAK |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation/Presenter</th>
</tr>
</thead>
</table>
| 10:35 a.m.   | **DoD Vaccine Effectiveness Report**  
Michael Cooper, Ph.D. CAPT, PHS  
Leader, Respiratory Pillar Activities  
Division of Global Emerging Infection Surveillance  
Armed Forces Health Surveillance Center |
| 10:55 a.m.   | **Vaccine Responses**  
Zhiping Ye, M.D., Ph.D.  
Senior Investigator  
Division of Viral Products  
Office of Vaccines Research and Review  
CBER/FDA |
| 11:15 a.m.   | **Candidate Vaccine Strains & Potency Reagents**  
Manju Joshi, Ph.D.  
Lead Biologist  
Division of Biological Standards & Quality  
Office of Compliance and Biologics Quality  
CBER/FDA |
| 11:35 a.m.   | **Comments from Manufacturers**  
Matthew Downham, Ph.D.  
Associate Director,  
Biopharmaceutical Development  
AstraZeneca/MedImmune |
| 11:55 a.m.   | **LUNCH** |
| 12:50 p.m.   | **Open Public Hearing** |
| 1:50 p.m.    | **Committee Discussion, Voting and Recommendations** |
| 3:00 p.m.    | **Adjournment** |